(Gln22)-Amyloid beta-Protein (1-40) incorporates a glutamine substitution at residue 22 that influences aggregation kinetics and fibril morphology. This variant is frequently used to investigate early events in amyloid formation. Its altered structural dynamics aid studies of protein misfolding and biochemical stability. The peptide supports research on molecular determinants affecting aggregation pathways.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More